PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: ...

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, ...

Equities researchers at HC Wainwright boosted their Q2 2025 earnings estimates for shares of BriaCell Therapeutics in a research report issued on Monday, February 3rd. HC Wainwright analyst E. Bodnar ...

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” ...

Investing.com -- BriaCell Therapeutics Corp. (NASDAQ: BCTX ...

BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) had its price target lifted by investment analysts at HC Wainwright from $15.00 to $32.00 in a research note issued to investors on ...

Therapeutics trading halted, volatility trading pauseMaximize Your Portfolio with Data Driven Insights:Leverage the ...

周二，H.C. Wainwright分析师Emily Bodnar将Briacell Therapeutics (NASDAQ: BCTX ...

Shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) climbed 10% following the announcement of a significant clinical response ...

BriaCell (NASDAQ: BCTX, BCTXW) (TSX: BCT) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, has ...

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, ...

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage ...